Valeant Pharmaceuticals International, Inc. (VRX) Closed at $13.47

The investigation concerns possible violations of securities law committed by Valeant Pharmaceuticals Intl (NYSE: VRX) management that has led to significant losses to investors. By reviewing stock prices from the stock market history of the company and examining its analysts ratings can give an investment picture with updated information of stock which helps investors to make investing decision. Boeing had 40 analyst reports since August 26, 2015 according to SRatingsIntel. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has "Buy" rating given on Friday, November 20 by Mizuho. The rating was maintained by Canaccord Genuity with "Hold" on Wednesday, March 16. The rating was maintained by Scotia Capital with "Sector Outperform" on Tuesday, October 20. The rating was maintained by Barclays Capital on Thursday, May 11 with "Equal Weight". The company was maintained on Friday, May 5 by RBC Capital Markets.

On November 23 the company was downgraded to "Underperform" from " with a current price target of $11.00 in a statement from Mizuho. On Tuesday, September 29 the stock rating was initiated by Nomura with "Buy". VRX reported a change of 6.48% over the last week and performed 0.00% over the last month while its year to date (YTD) performance revealed an activity trend of -7.23%. Following the completion of the transaction, the director now owns 70,572 shares of the company's stock, valued at approximately $980,950.80. Nomura holds 5,225 shares. A total of 24.69 million shares exchanged at hands and its average trading volume is standing at 20.96 million shares. Consequently, the shares traded in green and surged as much as 6.40% during active trading yesterday. The Shareholder Yield of Valeant Pharmaceuticals International, Inc. It has outperformed by 39.70% the S&P500. 14 analysts on average projected earnings of $0.96 per share for the current quarter. The hedge fund run by Francis Chou held 1.96 million shares of the health care company at the end of 2016Q4, valued at $28.47 million, up from 1.45 million at the end of the previous reported quarter. Its down 0.10, from 0.88 in 2016Q3. 13 funds opened positions while 32 raised stakes. Blair William Il reported 42,868 shares. Hanseatic Mngmt Svcs Inc reported 38,849 shares. Oaktree Cap Management Lp invested 0.11% of its portfolio in Nationstar Mortgage Holdings Inc (NYSE:NSM). Guardian Life Ins Of America has 0.05% invested in Boeing Co (NYSE:BA). Aperio Gru Ltd Liability Corp holds 0% or 24,995 shares in its portfolio.

About 487,073 shares traded. OLD Mutual Customised Solutions Proprietary Ltd. now owns 11,900 shares of the specialty pharmaceutical company's stock worth $131,000 after buying an additional 9,300 shares in the last quarter. Senzar Asset Management Limited Liability Corporation reported 400,588 shares. National Bank & Trust Of Mellon holds 0% or 119,271 shares. Three investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Therefore 31% are positive. The rating was maintained by Rodman & Renshaw with "Buy" on Wednesday, March 16. On Tuesday, September 13 the stock rating was maintained by Jefferies with "Hold". Valley Advisers owns 99 shares for 0% of their portfolio. LAURO JEFFREY ALAN also bought $6,688 worth of O'Reilly Automotive Inc (NASDAQ:ORLY) shares. The High end of the forecast is $1.16 per share, while the Low end is $0.63 per share.

Earnings per share (EPS) breaks down the profitability of the company on a single share basis, and for Valeant Pharmaceuticals International, Inc. the EPS stands at 0.69 for the previous quarter, while the analysts predicted the EPS of the stock to be 0.63, suggesting the stock exceeded the analysts' expectations. It has underperformed by 65.21% the S&P500.

Investors sentiment decreased to 0.78 in 2016 Q4. Its up 0.49, from 0.62 in 2016Q3. It dived, as 82 investors sold VRX shares while 87 reduced holdings. 49 funds opened positions while 82 raised stakes.

Investors appeared to see Paulson's becoming a director as a vote of confidence in Valeant, sending its US-listed shares up 5.1. percent at $13.29. Compass Point downgraded the shares of NSM in report on Thursday, January 12 to "Sell" rating. 125,100 were accumulated by Blackrock Grp Limited. Franklin Resources, California-based fund reported 233,866 shares. New York-based D E Shaw & Com has invested 0.04% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Apriem holds 700 shares or 0% of its portfolio. The stock decreased 0.06% or $0.04 during the last trading session, reaching $62.66. Riggs Asset Managment Company has 4,193 shares for 0.03% of their portfolio.

Shares of Valeant Pharmaceuticals International, Inc. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 48.51% since June 20, 2016 and is downtrending. Ftb Advsrs reported 0.01% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Warren Averett Asset Management has 0.05% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.